Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK239512 for Remyelination in RRMS
NCT01772199Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of gsk239512 in relapsing-remitting multiple sclerosis (RRMS), sponsored by GSK. Started Feb 2013; status: completed.
02
Drugs
gsk239512
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01772199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772199.